Gene Therapy Is Showing Promise As a Cancer Fighter. Aventis, Schering-Plough Launch Advanced Trials

Article Abstract:

Aventis and Schering-Plough have both launched phase 3 trials of their anti-cancer therapy, which puts cancer gene therapy further along than any other area of gene therapy research.

HEALTH SERVICES, Cancer Therapy, Ambulatory Health Care Services, Cancer treatment, Aventis CropScience S.A.

---

Trials on Humans Will Begin for Drug Based on Genes. Human Genome Sciences Extends Lead Over Rivals

Article Abstract:

Human Genome Sciences Inc. (Rockville, MD) received approval from the FDA for a drug trial of a B-lymphocyte stimulator, which has shown promise in rebuilding impaired immune systems. The test will concentrate on cancer and elderly patients.

European Union, Biological Product (except Diagnostic) Manufacturing, Biological products exc. diagnostic, Immunostimulants, Care and treatment, Laws, regulations and rules, Biological products industry, Human Genome Sciences Inc., HGSI, United States. Food and Drug Administration, Immune system, Lymphocytes, Immunologic adjuvants

---

AIDS vaccine tests set for Africa, Asia (Rhone-Poulenc, VaxGen plan separate trials)

Article Abstract:

Two companies have announced their intention to test experimental AIDS vaccines in Africa and Thailand. France's Rhone-Poulenc has already begun testing in Uganda. California-based VaxGen Inc. has received permission from the government of Thailand to launch the largest AIDS vaccine clinical trial outside of the United States.

Research and Testing Services, Pharmaceutical Preparation Manufacturing, Pharmaceutical preparations, Viral Disease R&D, Antiinfective Preparations NEC, Pharmaceutical industry, Anti-infective agents, Abstract, Viral research, Rhone-Poulenc S.A., VaxGen Inc.

Similar abstracts:

• Abstracts: NTT takes on the big boys; having triumphed at home Japan's giant steps into international ring. (Nippon Telegraph and Telephone Corp.)
• Abstracts: Salomon grabs top slot in Euro debt issuance; Newly muscular staff helps win bond battle. Making the case for growth
• Abstracts: Ocean Spray drops its lawsuit over PepsiCo's Tropicana deal. Coca-Cola find it's difficult to give up school contracts
• Abstracts: Progress at PetroChina? Public oil firm aims to strike out on its own. Zhenhai stands to gain from China's oil-sector reforms
• Abstracts: Nortel negotiates to buy Swiss plant from JDS for $3 billion in stock. Nortel Networks will acquire Xros in stock deal

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.